Global Binge Eating Disorder Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Binge Eating Disorder treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Amygdala Neurosciences Inc, Chronos Therapeutics Ltd, F. Hoffmann-La Roche Ltd, Sosei Heptares, Novo Nordisk AS and others.
A Significant contribution to the Binge Eating Disorder pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Binge Eating Disorder pipeline included 10 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Binge Eating Disorder condition and increased access to investments is encouraging growth of Binge Eating Disorder drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Binge Eating Disorder drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Binge Eating Disorder therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Binge Eating Disorder pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Binge Eating Disorder. Further, orphan drug status, fast track designation, grants awarded and other special status for Binge Eating Disorder pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Binge Eating Disorder pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Binge Eating Disorder Pipeline candidates-
A Significant contribution to the Binge Eating Disorder pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Binge Eating Disorder pipeline included 10 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Binge Eating Disorder condition and increased access to investments is encouraging growth of Binge Eating Disorder drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Binge Eating Disorder drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Binge Eating Disorder therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Binge Eating Disorder pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Binge Eating Disorder. Further, orphan drug status, fast track designation, grants awarded and other special status for Binge Eating Disorder pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Binge Eating Disorder pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Binge Eating Disorder Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Binge Eating Disorder drugs
- Late phase: Phase 3 and in-approval Binge Eating Disorder drugs
- Company overview
- Snapshot
- Binge Eating Disorder therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Binge Eating Disorder- Disease Overview
2.2 Binge Eating Disorder- Pipeline Snapshot
2.3 Binge Eating Disorder- Pipeline Drugs by Phase
2.4 Binge Eating Disorder- Pipeline Drugs by Company
2.5 Binge Eating Disorder- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Amygdala Neurosciences Inc Binge Eating Disorder Drug Pipeline, H2- 2019
3.2 Chronos Therapeutics Ltd Binge Eating Disorder Drug Pipeline, H2- 2019
3.3 F. Hoffmann-La Roche Ltd Binge Eating Disorder Drug Pipeline, H2- 2019
3.4 Novo Nordisk AS Binge Eating Disorder Drug Pipeline, H2- 2019
3.5 Omeros Corp Binge Eating Disorder Drug Pipeline, H2- 2019
3.6 Opiant Pharmaceuticals Inc Binge Eating Disorder Drug Pipeline, H2- 2019
3.7 Seropeutics LLC Binge Eating Disorder Drug Pipeline, H2- 2019
3.8 Sosei Heptares Binge Eating Disorder Drug Pipeline, H2- 2019
3.9 Sunovion Pharmaceuticals Inc Binge Eating Disorder Drug Pipeline, H2- 2019
3.10 Takeda Pharmaceutical Co Ltd Binge Eating Disorder Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Binge Eating Disorder- Phase 1 Drug Details
4.2 Binge Eating Disorder- Phase 1 Drug Overview
4.3 Binge Eating Disorder- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Binge Eating Disorder- Phase 2 Drug Details
5.2 Binge Eating Disorder- Phase 2 Drug Overview
5.3 Binge Eating Disorder- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Binge Eating Disorder- Phase 3 Drug Details
6.2 Binge Eating Disorder- Phase 3 Drug Overview
6.3 Binge Eating Disorder- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Binge Eating Disorder- Pre-clinical Phase Drug Details
7.2 Binge Eating Disorder- Pre-clinical Phase Drug Overview
7.3 Binge Eating Disorder- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Binge Eating Disorder- Disease Overview
2.2 Binge Eating Disorder- Pipeline Snapshot
2.3 Binge Eating Disorder- Pipeline Drugs by Phase
2.4 Binge Eating Disorder- Pipeline Drugs by Company
2.5 Binge Eating Disorder- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Amygdala Neurosciences Inc Binge Eating Disorder Drug Pipeline, H2- 2019
3.2 Chronos Therapeutics Ltd Binge Eating Disorder Drug Pipeline, H2- 2019
3.3 F. Hoffmann-La Roche Ltd Binge Eating Disorder Drug Pipeline, H2- 2019
3.4 Novo Nordisk AS Binge Eating Disorder Drug Pipeline, H2- 2019
3.5 Omeros Corp Binge Eating Disorder Drug Pipeline, H2- 2019
3.6 Opiant Pharmaceuticals Inc Binge Eating Disorder Drug Pipeline, H2- 2019
3.7 Seropeutics LLC Binge Eating Disorder Drug Pipeline, H2- 2019
3.8 Sosei Heptares Binge Eating Disorder Drug Pipeline, H2- 2019
3.9 Sunovion Pharmaceuticals Inc Binge Eating Disorder Drug Pipeline, H2- 2019
3.10 Takeda Pharmaceutical Co Ltd Binge Eating Disorder Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Binge Eating Disorder- Phase 1 Drug Details
4.2 Binge Eating Disorder- Phase 1 Drug Overview
4.3 Binge Eating Disorder- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Binge Eating Disorder- Phase 2 Drug Details
5.2 Binge Eating Disorder- Phase 2 Drug Overview
5.3 Binge Eating Disorder- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Binge Eating Disorder- Phase 3 Drug Details
6.2 Binge Eating Disorder- Phase 3 Drug Overview
6.3 Binge Eating Disorder- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Binge Eating Disorder- Pre-clinical Phase Drug Details
7.2 Binge Eating Disorder- Pre-clinical Phase Drug Overview
7.3 Binge Eating Disorder- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
